Biogen Idec Inc. (BIIB) Stock Research, Analysis & News
Quick Analysis on Biogen Idec Inc. (BIIB) Stock as of September 20, 2017
 | Previous Closing Price $317.93 is above 50 day moving average of $300.47 |
| Previous Closing Price $317.93 is above 200 day moving average of $278.47 |
| The Price/Earnings To Growth ratio (PEG) is great than 1 |
 | The Stock pays no dividend |
| The closing price $317.93 is less than 4.42% away from its one year target price of $331.99 |
 | Current Short Ratio 2.28 is great than 1 |
(See more information about Biogen Idec Inc. (BIIB) Stock below)
Biogen Idec Inc. (BIIB) Stock Profile Summary
Biogen Idec Inc., a biotechnology company, develops, manufactures, and commercializes novel therapeutics in the areas of neurology, oncology, immunology, cardiopulmonary, and hemophilia in the United States and internationally. The companys marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, low-grade or follicular, CD20-positive, and B-cell Non-Hodgkins Lymphoma (NHL); TYSABRI to treat relapsing MS; and FUMADERM for the treatment of severe psoriasis. Its products under development consist of BG-12, a Phase III clinical trial product for the treatment of MS; Humanized Anti-CD20 MAb, a Phase III clinical trial product for the treatment of rheumatoid arthritis and lupus nephritis; Lixivaptan, a Phase III clinical drug for the treatment of Hyponatremia; Daclizumab, a Phase II monoclonal antibody that is being tested in relapsing MS; and Fampridine, an oral compound as a treatment to improve walking ability in people with MS. The companys products under preclinical stage comprise BIIB014, Ocrelizumab, Neublastin, LINGO, and BART for neurology; Hsp90 Inhibitor, GA101, Anti-IGF-1R, Volociximab, Anti-CRIPTO, RAF Inhibitor, and Anti-Fn14 for oncology; Anti-TWEAK, Anti-CD40L Fab, and Anti-FcRn for immunology; and Long-acting rFactor VIII for hemophilia. It has collaboration agreements with Neurimmune SubOne AG; Cardiokine Biopharma LLC; UCB, S.A.; Swedish Orphan Biovitrum AB; Facet Biotech Corporation; Vernalis plc; and Schering AG. Biogen Idec Inc. was formerly known as IDEC Pharmaceuticals Corporation and changed its name on November 13, 2003. The company was founded in 1985 and is based in Weston, Massachusetts.
Biogen Idec Inc. (BIIB) Stock Key Statistics Research and Analysis as of September 20, 2017
| Stock Exchange | NMS |
| Market Capitalization | $67.31B
|
| Trade Volume (Average Trading Volume) | 534,995 (1,360,980) |
| Price/Sales | 5.74 |
| Price/Book | 5.80 |
| P/E | 20.89 |
| Earning/Share | $15.24 |
| Current Year EPS Estimate | $21.50 |
| Next Year EPS Estimate | $23.14 |
| Previous Closing Price | $317.93 |
| 50 Day Price Moving Average | $300.47 |
| 200 Day Price Moving Average | $278.47 |
| 1 yr Target Price | $331.99 |
| PEG Ratio | 2.33 |
| Short Ratio | 2.28 |
| EBITDA | $6.42B |
Biogen Idec Inc. (BIIB) Stock Competitor Research and Analysis
Mutual Funds with Biogen Idec Inc. (BIIB) Stock in its top 10 holdings
ETFs with Biogen Idec Inc. (BIIB) Stock in its top 10 holdings
Stock Research on Biogen Idec Inc. (BIIB)
- Biogen (BIIB) Tops on Q1 Earnings, Slight Revenue Miss [Apr 21, 2016]
- Biogen (BIIB) Beats on 1Q Earnings by a Wide Margin [Apr 21, 2016]
- The Zacks Analyst Blog Highlights: Gilead, Amgen, Regeneron, Ionis and Biogen [Mar 28, 2016]
- Gilead & Biogen's Patent Woes, Amgen Scores Win in Patent Litigation [Mar 24, 2016]
- The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Gilead Sciences, Biogen, Amgen and Regeneron Pharmaceuticals [Mar 07, 2016]
- Get additional research reports on Biogen Idec Inc. (BIIB)
Latest Market News on Biogen Idec Inc. (BIIB)
Click here to find the latest news on Biogen Idec Inc. (BIIB)
Looking for Market Opportunties?
Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center
See other companies in the same industry
Bristol-Myers Squibb Company (BMY) Amgen Inc. (AMGN) Genzyme Corp. (GENZ) Gilead Sciences Inc. (GILD) Life Technologies Corporation (LIFE) Teva Pharmaceutical Industries Limited (TEVA) Watson Pharmaceuticals Inc. (WPI) King Pharmaceuticals Inc. (KG) Mylan, Inc. (MYL) Pfizer Inc. (PFE) Johnson & Johnson (JNJ) GlaxoSmithKline plc (GSK) Sanofi-Aventis (SNY) Novartis AG (NVS) AstraZeneca PLC (AZN)
Research on Biogen Idec Inc. (BIIB)
